Pharmaxis (PXS) Stock Price, News & Analysis

Company Overview

Pharmaxis Ltd, a clinical stage drug development company, engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. It operates through Mannitol Respiratory Business and New Drug Development segments. The company provides Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test for the treatment of asthma. It's product pipeline comprises oral pan-Lysyl Oxidase Inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events such as accidents, surgery, and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases including kidney, pulmonary, liver, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. The company also offers Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 721,139 shs
• Average Volume: N/A
• Market Capitalization: A$20.23 million
• P/E Ratio: N/A
• Dividend Yield: 6.41%
• Price Target: N/A
• Consensus Rating: N/A

PXS Stock Analysis - Frequently Asked Questions

How were Pharmaxis' earnings last quarter?

Pharmaxis Ltd (ASX:PXS) posted its earnings results on Thursday, February, 14th. The company reported ($0.03) EPS for the quarter. Pharmaxis had a negative trailing twelve-month return on equity of 143.13% and a negative net margin of 161.24%.

What other stocks do shareholders of Pharmaxis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Incannex Healthcare (IHL) and XPO (XPO).

Company Calendar

• Last Earnings: 2/14/2019
• Today: 7/03/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Transportation
• Current Symbol: ASX:PXS
• CIK: N/A
• Web: www.pharmaxis.com.au
• Phone: +61-2-94547200
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 0.21
• Net Income: -A$18.43 million
• Net Margins: -161.24%
• Pretax Margin: N/A
• Return on Equity: -143.13%
• Return on Assets: -48.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.21
• Quick Ratio: 14.73

Sales & Book Value

• Annual Sales: A$11.89 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.32
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 722,610,000
• Free Float: N/A
• Market Cap: A$20.23 million
• Optionable: Not Optionable
• Beta: 0.64